Clinicopathological features and outcomes of patients with gastric cancer: A single-center experience

Table 1 Demographic data of the 796 patients with gastric cancer n (%)

Age (yr)	Median	58 (22-90)
Sex	Male	552 (69)
	Female	244 (31)
Median follow-up time	12 mo (range: 1-276 mo)
Median survival	12 mo (range: 11.5-12.4 mo)
Tumor location	Pyloric + antrum	362 (45.4)
	Large and small curvature	252 (31.6)
	Cardio-esophageal	97 (12.2)
	Diffuse	9 (1.1)
Stage	Stage I	29 (3.6)
	Stage II	43 (5.4)
	Stage III	195 (24.5)
	Stage IV	393 (49.3)
Type of surgery	Total gastrectomy	265 (33.2)
	Subtotal gastrectomy	174 (21.8)
	Inoperable/palliative	341 (42.8)
Treatment	Adjuvant	352 (44.2)
	Metastatic	394 (49.4)
	Untreated follow-up	50 (3.9)
Histology	Adenocarcinoma (intestinal type)	493 (61.9)
	Signet ring cell (diffuse)	254 (31.9)
	Neuroendocrine	24 (3)
	Others	8 (1.1)
In metastasis	Peritonitis carcinomatosa	193 (24.2)
	Liver	169 (21.2)
	Lymphadenopathy	73 (9.2)
	Liver + peritoneum	35 (4.4)
	Lung	28 (3.5)
	Pleural effusion + acid	24 (3)
	Bone	23 (2.9)
	Others	17 (2.1)
Recurrence in	Peritonitis carcinomatosa	61 (40.1)
	Liver	36 (23.7)
	Lymphadenopathy	24 (15.8)
	Local	14 (9.2)
	Pleural/lung	12 (7.9)
	Others	5 (5)

Table 2 Treatment received by the patients with gastric cancer (n = 796) n (%)

	Treatment
Adjuvant therapy	5-FU-LV	222 (27.9)
	5-FU-LV/cisplatin	43 (5.4)
	Untreated follow-up	58 (7.3)
	Others	17 (2.1)
Metastatic series 1	5-FU-LV	32 (4)
	DCF	152 (19.1)
	ECF	77 (9.7)
	5-FU-LV/cisplatin	121 (15.2)
	Palliative treatment	112 (14.1)
	Cisplatin/capecitabine	20 (2.5)
	Others	31 (3.9)
Metastatic series 2	DCF	31 (3.9)
	5-FU-LV/cisplatin	19 (2.4)
	ECF	14 (2.3)
	Irinotecan/cisplatin	17 (2.1)
	Supportive	267 (33.5)
	Others	32 (4)

5-FU-LV: 5-Fluorouracil plus leucovorin; CF: Cisplatin-fluorouracil; DCF: Docetaxel-cisplatin-fluorouracil; ECF: Epirubicin-cisplatin-5FU.

Table 3 Disease-free survival with chemotherapy and without chemotherapy in metastasis-free gastric cancer

Therapeutic approach	n	Average (mo)	Standard deviation	Minimum (mo)	Maximum (mo)
5-FU-LV	222	21.04b	19.912	2	120
Untreated follow-up	58	30.42	24.512	6	120
CF	43	19.00b	24.452	3	120
Others	17	21.00b	24.512	3	72

^bP < 0.01 vs untreated follow-up. 5-FU-LV: 5-Fluorouracil plus leucovorin; CF: Cisplatin-fluorouracil.

Table 4 Time to first progression and time to 2^nd progression according to treatment (chemotherapy or supportive) care in patients with metastatic gastric cancer (P < 0.001)

Therapeutic approach	n	Average (mo)	Standard deviation	Minimum (mo)	Maximum (mo)
First series of chemotherapy and time to progression
DCF	152	6.56	2.869	1	18
ECF	77	4.56	9.021	1	48
CF	121	4.15	5.546	1	39
Supportive	112	3.85	9.951	2	60
Others	38	5.24	11.954	1	60
Second series of chemotherapy and time to progression
DCF	31	4.38	3.921	2	15
ECF	14	3.71	2.443	2	10
CF	19	3.76	3.914	3	18
Supportive	267	3.39	1.871	1	12
Others	17	3.75	1.528	1	7

5-FU-LV: 5-Fluorouracil plus leucovorin; CF: Cisplatin-fluorouracil; DCF: Docetaxel-cisplatin-fluorouracil; ECF: Epirubicin-cisplatin-5FU.

Table 5 Comparison of treatment approaches in the first and second series of treatments in metastatic gastric cancer patients

1st-series treatment approach	P value	2nd-series treatment approach	P value
DCF vs 5-FU-LV	0.043	DCF vs ECF	0.050
DCF vs others	0.010	DCF vs Supportive	0.042
DCF vs Supportive	< 0.001	Supportive vs ECF	0.500
DCF vs ECF	< 0.001	DCF vs others	0.605
DCF vs CF	0.480	Irinotecan/Cisp vs ECF	0.423
ECF vs CF	0.960	Supportive vs Irinotecan/Cisp	0.100
Supportive vs ECF	< 0.01	DCF vs Irinotecan/Cisp	0.672

5-FU-LV: 5-Fluorouracil plus leucovorin; CF: Cisplatin-fluorouracil; DCF: Docetaxel-cisplatin-fluorouracil; ECF: Epirubicin-cisplatin-5FU.